ELGX Endologix Inc

Endologix, Inc. (Nasdaq:ELGX) today announced that it has filed with the Securities and Exchange Commission a shelf registration statement on Form S-3 which, when declared effective, will permit Endologix, from time to time, to offer and sell up to $50 million of common stock. The company believes that a shelf registration, which has become a common financing tool in the healthcare industry, will give it greater flexibility as it finances its business in the future. Endologix plans to use the proceeds from any offerings under this registration statement to accelerate its sales force recruitment and expand its marketing efforts in the United States, to commercialize a broader and enhanced family of Powerlink(R) System products and for working capital to support expected growth in sales of its Powerlink System. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. About Endologix Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft (ELG) for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the thirteenth leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com. Except for historical information contained herein, this news release contains forward-looking statements, including those relating to the effectiveness of the shelf registration statement, the completion of any future offerings under the shelf registration statement and the use of proceeds from such offerings, the accuracy of which are necessarily subject to risks and uncertainties, including risks related to changes in market acceptance of the Powerlink System, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix, all as more fully described in the risk factors and other matters set forth in Endologix's Annual Report on Form 10-K for the year ended December 31, 2005, and Endologix's other filings with the Securities and Exchange Commission.